# A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

> **NCT02712112** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 51 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors (GISTs)

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT02712112
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-16
- **Primary completion:** 2019-06-15
- **Final completion:** 2019-06-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02712112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02712112, "A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02712112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*